Jazz Pharmaceuticals (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $4.10 EPS for the quarter, beating analysts’ consensus estimates of $3.19 by $0.91, Briefing.com reports. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The company had revenue of $537.70 million during the quarter, compared to analyst estimates of $523.92 million. During the same period last year, the business earned $3.58 earnings per share. Jazz Pharmaceuticals’s revenue was up 14.6% compared to the same quarter last year. Jazz Pharmaceuticals updated its FY19 guidance to $15.50-16.15 EPS.

Jazz Pharmaceuticals stock traded up $4.18 during mid-day trading on Friday, reaching $130.14. 747,500 shares of the company traded hands, compared to its average volume of 551,937. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. The firm’s 50 day moving average price is $124.77 and its 200 day moving average price is $131.70. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 10.63, a P/E/G ratio of 1.57 and a beta of 1.09. Jazz Pharmaceuticals has a 52-week low of $113.52 and a 52-week high of $154.44.

JAZZ has been the subject of a number of analyst reports. HC Wainwright restated a “hold” rating and issued a $147.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 8th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 11th. ValuEngine upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 price objective for the company. in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the stock. Jazz Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $167.33.

In other news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $130.00, for a total transaction of $65,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,371 shares of company stock worth $730,575. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Growth Stocks, What They Are, What They Are Not

Earnings History for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.